39 Omkar Pharmachem Ltd.

Date: 30.05.2022

To, **B S E Limited**, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

## Sub: Annual Secretarial Compliance Report for the year ended 31st March, 2022

Company Scrip Code: 532167

Dear Sir/Ma'am,

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read along with SEBI Circular no CIR/CFD/CMD 1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company issued by M/s. Maulik Bhavsar & Associates, Practicing Company Secretaries for the financial year 2021 -22.

This is for the information of the Exchange and the Members.

Thanking you, Yours faithfully, For **Omkar Pharmachem Limited** 

ARMAC

Bhawani Shankar Govar (Managing Director) DIN: 03255804 Address: House No. - 155/2, First Floor, Gali No - 2 Near Gurudwara, Govindpuri, Kalkaji- 110019 Delhi

Enc-a/a



## MAULIK BHAVSAR & ASSOCIATES Company Secretaries

### Secretarial compliance report of OMKAR PHARMACHEM LIMITED for the year ended 31.03.2022

#### To,

#### OMKAR PHARMACHEM LIMITED

# 310, WALL STREET-1, NEAR GUJARAT COLLEGE CROSS ROAD, ELLISBRIDGE AHMEDABAD-380006 GUJARAT

We have conducted the Secretarial Compliance Audit of OMKAR PHARMACHEM LIMITED as per the applicable SEBI (Securities and Exchange Board of India) Regulations and the circulars/ guidelines issued thereunder for the Financial Year ended 31st March 2022. The audit was conducted in a manner that provided me with a reasonable basis for evaluating the statutory compliances and expressing my opinion thereto.

We, MAULIK BHAVSAR & ASSOCIATES, Practicing Company Secretary, Ahmedabad have examined:

- (a) all the documents and records made available to us and explanation provided by Omkar Pharmachem Limited ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity, https://www.omkarpharmachem.co.in/
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March, 2022 in respect of compliance with the provisions of :

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 : N.A. during the year under review
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

12A, Manmohan Complex, B/h. Navrangpura Police Station, Navrangpura, Ahmedabad – 380009 Mo : 9428599185, Mail : <u>csmaulikbhavsar@gmail.com</u> Website : <u>http://www.csmaulikbhavsar.com/</u>

## MAULIK BHAVSAR & ASSOCIATES Company Secretaries



- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; N.A. during the year under review
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; N.A. during the year under review
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; N.A. during the year under review
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; N.A. during the year under review
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) SEBI (Depository and Participant) Regulation, 2018

and circulars/ guidelines issued thereunder; and based on the above examination, I/We hereby report that, during the Review Period:

- (a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder,
- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my/our examination of those records.
- (c) As per the information provided by the Management of the company, there is no such action taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges.
- (d) The listed entity is not required to take any actions as there was no observations made in previous reports for the year ended 31<sup>st</sup> March, 2021:

Note : As per the information and related documents provided to us, We have verified the disclosures and compliances to be made by the Listed entity – Omkar Pharmachem Limited only during FY 2021-22.

Place : Ahmedabad Date : 28.05.2022 AND DE LESS

For Maulik Bhavsar & Associates Company Secretaries

semling of Bharder

Maulik Bhavsar (Proprietor) Mem. No. 11139, CP No. 11591

UDIN F011139D000416137

12A, Manmohan Complex, B/h. Navrangpura Police Station, Navrangpura, Ahmedabad – 380009 Mo : 9428599185, Mail : <u>csmaulikbhavsar@gmail.com</u> Website : <u>http://www.csmaulikbhavsar.com/</u>